KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $929.0 million.

  • Royalty Pharma's Cash & Equivalents fell 1.17% to $938.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $938.9 million, marking a year-over-year decrease of 1.17%. This contributed to the annual value of $929.0 million for FY2024, which is 94.76% up from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Cash & Equivalents is $929.0 million, which was up 94.76% from $477.0 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Cash & Equivalents ranged from a high of $1.7 billion in FY2022 and a low of $477.0 million during FY2023.
  • Over the past 3 years, Royalty Pharma's median Cash & Equivalents value was $929.0 million (recorded in 2024), while the average stood at $1.0 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 2,789.81% in 2020, then slumped by 72.12% in 2023.
  • Over the past 5 years, Royalty Pharma's Cash & Equivalents (Yearly) stood at $1.0 billion in 2020, then skyrocketed by 52.78% to $1.5 billion in 2021, then rose by 11.01% to $1.7 billion in 2022, then plummeted by 72.12% to $477.0 million in 2023, then soared by 94.76% to $929.0 million in 2024.